强生达雷妥尤单抗进入“百亿美元俱乐部”几乎已无悬念之际，蓄势已久的CD38药物终于在2025年开年展现出了燎原态势。 2025年的第二周，CD38靶点 ...

赛诺菲今日宣布，旗下抗CD38单抗赛可益 ® （艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA）批准，用于与泊马度胺和地塞米松联合用药 ...

1月10日，康诺亚宣布，就潜在同类最优的靶向CD38人源化单克隆抗体CM313与Timberlyne Therapeutics达成独家授权许可协议。 CM313是由康诺亚自主研发的靶向 ...

中国网财经1月9日讯 赛诺菲今日宣布，旗下抗CD38单抗赛可益(艾沙妥昔单抗注射液)获得国家药品监督管理局(NMPA)批准，用于与泊马度胺和地塞米松 ...

Central to the pathogenesis of VaD are cerebrovascular endothelial cell (CEC) dysfunction, blood-brain barrier (BBB) disruption, and neuroinflammation. CD38, an enzyme involved in neuroinflammation ...

Background CD38 is a NAD+ consuming enzyme ubiquitously expressed on immune cells and its expression increases in several pathological conditions, including Rheumatoid Arthritis (RA) [1, 2].

charite.de We recently reported the successful treatment of two systemic lupus erythematosus (SLE) patients with daratumumab, a CD38-targeting human monoclonal antibody, demonstrating a clinically ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting ...